Abstract: The present invention relates to a method for activating tumor-infiltrating lymphocytes (TILs) in a subject in need, particularly by administering to the subject a fermented composition generated via fermentation of symbiotic microbiota in a medium.
Type:
Grant
Filed:
January 9, 2019
Date of Patent:
November 23, 2021
Assignee:
MICROBIO CO., LTD.
Inventors:
Kung-Ming Lu, Min-Liang Kuo, Ai-Jen Yang
Abstract: Combined therapy of cancer using an immune check point modulators (e.g., an immune checkpoint inhibitor) and a fermented product, which may be prepared using symbiotic microbiota.
Abstract: Combined therapy of cancer using an immune check point modulators (e.g., an immune checkpoint inhibitor) and a fermented product, which may be prepared using symbiotic microbiota.
Abstract: The present invention relates to a method for activating tumor-infiltrating lymphocytes (TILs) in a subject in need, particularly by administering to the subject a fermented composition generated via fermentation of symbiotic microbiota in a medium.
Type:
Application
Filed:
January 9, 2019
Publication date:
July 11, 2019
Applicant:
Microbio Co., Ltd.
Inventors:
Kung-Ming Lu, Min-Liang Kuo, Ai-Jen Yang
Abstract: Combined therapy of cancer using an immune check point modulators (e.g., an immune checkpoint inhibitor) and a fermented product, which may be prepared using symbiotic microbiota.
Abstract: The present invention relates to use of a fermented soy extract as a prebiotic composition to protect beneficial bacteria in the gastrointestinal tract of an animal. Particularly, the fermented soy extract of the invention exhibits the prebiotic activity even under an antibiotic treatment. Also disclosed is combined use of an antibiotic and the fermented soy extract of the invention, which has advantages over administration of the antibiotic alone, such as decreasing the effective dose of the antibiotic and/or reducing side effects resulting from the antibiotic treatment.
Type:
Grant
Filed:
July 20, 2011
Date of Patent:
February 16, 2016
Assignee:
MICROBIO CO., LTD.
Inventors:
Ming-Hong Chuang, Cheng Der Tony Yu, Kung-Ming Lu
Abstract: The present invention relates to use of a fermented soy extract as a prebiotic composition to protect beneficial bacteria in the gastrointestinal tract of an animal. Particularly, the fermented soy extract of the invention exhibits the prebiotic activity even under an antibiotic treatment. Also disclosed is combined use of an antibiotic and the fermented soy extract of the invention, which has advantages over administration of the antibiotic alone, such as decreasing the effective dose of the antibiotic and/or reducing side effects resulting from the antibiotic treatment.
Type:
Application
Filed:
July 20, 2011
Publication date:
March 8, 2012
Applicant:
MICROBIO CO., LTD.
Inventors:
MING-HONG CHUANG, CHENG DER TONY YU, KUNG-MING LU
Abstract: A novel microorganism designated as Bacillus amyloliquefaciens F5H-5 and a use of a fermented Glycine max (L.) extract prepared by fermenting an aqueous Glycine max (L.) extract with the microorganism in inhibiting 15-lipoxygenase are provided. In particular, the fermented Glycine max (L.) extract can be used in preventing and/or treating a disease in which 15-lipoxygenase inhibition is implicated in a subject, such as cardiovascular diseases.
Abstract: The present invention relates to the preparation of therapeutic compositions comprising of fermented soy extracts made with lactic acid bacteria and the optional addition of at least a yeast. The invention also relates to therapeutic uses of such extracts in promoting general health, improving the health of subjects, preventing and/or treating cancer, preventing infections, reducing the incidence of infections, treating infections, treating asthma, treating inflammation, modulating the immune system and treating immune disorders.
Abstract: This invention relates to a use of a fermented Glycine max (L.) extract prepared by fermenting an aqueous Glycine max (L.) extract with at least one lactic acid bacteria together with at least one yeast, in enhancing Natural Killer (NK) cell activity. In particular, the fermented Glycine max (L.) extract can be used in preventing and/or treating a disease in which NK cell activation is implicated in a subject, such as cancer, infectious diseases and modulating the immune system.